Non-small-cell lung carcinoma (NSCLC) accounts for about three-quarters of all lung cancer histologies. Surgical resection is the preferred treatment and approximately 50 000 operations are performed in the United States alone each year (Lederle and Neiwoehner, 1995) . The overall prognosis for resected NSCLC is poor with less than a third of patients who undergo resection alive 5 years later (Humphrey et al., 1990) . There have been reports of many clinicopathological variables affecting prognosis of NSCLC. These have largely been examined in a univariate manner. They have included age, gender, TNM and other staging classifications, histopathological cell-types, oncogene expression and tumour biomarkers (Carney, 1992; Szabo and Mulshine, 1993) .
In considering a large number of factors together multivariate analyses are valuable for determining which factors are independently influencing outcome and for categorising their relative importance. In patients with inoperable lung carcinoma multivariate analaysis has shown the most important prognostic factors to be performance score, stage and weight loss in the previous 6 months (Stanley, 1980) . In small-cell lung carcinoma proportional hazard models have shown performance status, age, gender and number of metastases to be the most significant predictors (Albain et al., 1990; Gronowitz et al., 1990) .
We have previously shown that an estimate of NSCLC 'tumour volume' has a complex relationship with age which is dependent on patient gender and histological cell type (Pendleton et al., 1996) . In this study we (WHO, 1982) and nodal metastasis by the nodal score according to TNM classification criteria (UICC, 1987) . Staging was performed according to the criteria proposed by Mountain et al. (1993) (Splinter, 1992; Martini, 1990; Shields, 1993) . This has led to the examination of many clinicopathological variables that predict prognosis.
In clinical practice UICC stage (Mountain et al., 1991) has emerged as the single most important criterion for management (Greenberg et al., 1987) . It is those cases with stage I, II or Illa tumours that are generally considered suitable for surgery (Lederle and Neiwoehner, 1995) . In common with other studies (Mountain, 1993) we have found stage to be an extremely significant independent predictor of survival, and to supplant other factors we examined in a multivariate model.
Within the TNM scale, the development of mediastinal metastasis has been shown to be a critical transition affecting survival (Wantanabe, 1991) , and resectability (Mountain, 1993) . This corresponds to the development of UICC stage Illa from stage II. The results of this study support this finding, with no factor other than being in the stage Illa group having prognostic significance by multivariate analysis in these cases.
Contrary to some reports (Rosenthal and Curran, 1990) we did not find tumour cell-type to be of prognostic significance. There may be three reasons for this difference. Firstly, while tumour cell-type and tumour stage relationships are reported (Teeter et al., 1987; O'Rourke et al., 1987) A novel finding of this study is that 'tumour volume' is an extremely significant independent predictor of prognosis, and until the tumours have reached conditions for a classification of stage Illa, appears to be the key factor, superseding the transition from stage I to II, age, gender, tumour cell-type and nodal metastasis.
We have previously shown that 'tumour volume' is related in a complex manner to age, gender and tumour cell-type (Pendleton et al., 1996) . The omission of these factors from the multivariate model with the inclusion of 'tumour volume' indicates that they may together act to influence prognosis by affecting the 'tumour volume'.
There has been much investigation of the prognostic significance of molecular factors (Carney, 1992; Szabo and Mulshine, 1993) . While the inclusion of biomarker levels in a multivariate model has been shown to increase prognostic efficiency (Walop et al., 1990) , these techniques have not gained widespread clinical acceptance, are expensive and only available at a limited number of sites.
Thus, we conclude that while UICC staging remains the gold standard in prognosis and management of NSCLC, this study shows that an estimate of 'tumour volume', an easy-tocalculate measure that requires no specialist equipment, gives significant prognostic information over and above that of the UICC stage. We therefore suggest that estimation of 'tumour volume' should be considered as part of the routine postoperative prognostic work-up of NSCLC. Multivariate analyses including other factors such as oncogene expression and histopathological measures together with 'tumour volume' in prognosis of NSCLC merit further investigation.
